Equitable Access to Medicines Underpins Diabetes and CKD Directive
The 2022 guideline update published by the KDIGO organization for the care of people with diabetes and chronic kidney disease (CKD) highlighted the safety and expanded, evidence-based role agents from three drug classes: SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal mineralocorticoid receptor antagonists. But this key part of the guideline also underscored the challenges in …
Equitable Access to Medicines Underpins Diabetes and CKD Directive Read More »
